ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data TimingGlobeNewsWire • Thursday
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026GlobeNewsWire • 11/03/26
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to TradeZacks Investment Research • 10/29/26
ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial OfficerGlobeNewsWire • 10/06/26
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in SeptemberGlobeNewsWire • 09/01/26
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate HighlightsGlobeNewsWire • 08/13/26
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026GlobeNewsWire • 08/03/26
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's StudyBenzinga • 07/28/26
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease TrialGlobeNewsWire • 07/28/26
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's DiseaseGlobeNewsWire • 07/27/26
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026GlobeNewsWire • 07/14/26
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?Zacks Investment Research • 06/30/26
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to BuyZacks Investment Research • 06/12/26
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a BetZacks Investment Research • 06/12/26
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsGlobeNewsWire • 05/12/26
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor ConferenceNewsfile Corp • 04/13/26
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsGlobeNewsWire • 03/25/26
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)GlobeNewsWire • 03/18/26
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/04/26
ProMIS Neurosciences Announces Up to $175 Million Private Placement FinancingGlobeNewsWire • 01/30/26